Elanco Animal Health Inc. has recently released its 10-K report, providing an in-depth look into the company's performance and operations. Elanco is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The company's diverse product portfolio includes pet health products such as parasiticides, vaccines, and therapeutics, as well as farm animal products for cattle, swine, and poultry. Elanco's revenue for the year ended December 31, 2025, amounted to $4.7 billion, representing a 6% increase from the previous year. The company's revenue is diversified with approximately 51% derived from foreign currencies.
Elanco's gross profit for the same period was $2.6 billion, reflecting a 6% increase from the previous year. The company's research and development expenses totaled $368 million, representing a 7% increase, while marketing, selling, and administrative expenses amounted to $1.4 billion, marking a 9% increase. Additionally, Elanco incurred $237 million in asset impairment, restructuring, and other special charges, significantly higher than the $150 million recorded in the prior year. The company reported a net loss of $232 million for the year ended December 31, 2025, in contrast to a net income of $338 million in the prior year.
Elanco's product development and regulatory update included significant milestones such as the FDA approval and launch of new products like Bovaer, Zenrelia, Credelio Quattro, and AdTab, among others. The company also executed a restructuring plan to support margin expansion and optimize its global footprint, resulting in an expected global headcount reduction of approximately 300 employees. Elanco also refinanced its outstanding debt, divested its aqua business to Merck Animal Health, and executed a Purchase and Sale Agreement with affiliates of Blackstone, receiving proceeds of $295 million in exchange for the rights to the proceeds from qualifying future royalties and sales milestone payments owed by Tarsus Pharmaceuticals, Inc.
Elanco's 10-K report provides a comprehensive overview of the company's financial performance, strategic initiatives, and key milestones achieved in the year. The report underscores Elanco's commitment to advancing animal health and its efforts to drive innovation and growth in the global animal health industry. As a result of these announcements, the company's shares have moved 1.45% on the market, and are now trading at a price of $24.53. Check out the company's full 10-K submission here.
